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Abstract
Background: Slow coronary flow (SCF) is characterized by delayed opacification of epicardial
coronary vessels. SCF can cause ischemia and sudden cardiac death. We investigated the associa-
tion between presence and extent of SCF, and cardiovascular risk factors and hematologic indices.
Methods: In this study, 2467 patients who received coronary angiography for suspected or
known ischemic heart disease were retrospectively evaluated between April 2009 and Novem-
ber 2010. Following the application of exclusion criteria, our study population consisted of
57 SCF patients (experimental group) and 90 patients with age- and gender-matched subjects
who proved to have normal coronary angiograms (control group). Baseline hematologic indices
were measured by the automated complete blood count (CBC) analysis. The groups were
evaluated for cardiovascular risk factors and medications. Patients were categorized based on
the angiographic findings of vessels with or without SCF. Moreover, patients with SCF were
divided into subgroups relative to the extent of SCF.
Results: Among the 147 patients (mean age 52.7 ± 10.0, 53.7% male), mean platelet volume
(MPV) ranged from 6.5 fL to 11.7 fL (median 7.9 fL, mean 8.1 ± 0.8 fL). Diabetes (OR = 3.64,
95% CI 1.15–10.43, p = 0.03), hypercholesterolemia (OR = 4.94, 95% CI 1.99–12.21,
p = 0.001), smoking (OR = 3.54, 95% CI 1.43–8.72, p = 0.006), hemoglobin (OR = 1.69,
95% CI 1.22–2.36, p = 0.002), and MPV (OR = 2.52, 95% CI 1.43–4.44, p = 0.001)
were found to be the independent correlates of SCF presence. Only MPV (OR = 2.13, 95% CI
1.05–4.33, p = 0.03) was identified as an independent correlate of extent of SCF.
Conclusions: Elevated baseline MPV value was found to be an independent predictor of the
presence and extent of SCF. (Cardiol J 2012; 19, 4: 355–362)
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Introduction
Slow coronary flow (SCF) phenomenon is char-
acterized by delayed opacification of epicardial cor-
onary vessels in the absence of stenosis and/or con-
ditions such as coronary ectasia, coronary spasm,
valvular and myocardial heart disease, acute myo-
cardial infarction and coronary reperfusion therapy
[1]. Various studies have found the incidence of SCF
ranging between 1% and 7% in patients undergo-
356
Cardiology Journal 2012, Vol. 19, No. 4
www.cardiologyjournal.org
ing angiography [2, 3]. The reason behind varying
incidence rates derives from methodological differ-
ences. The underlying mechanism responsible for
SFC phenomenon is not known clearly. Nonethe-
less, mechanisms that are possibly involved in the
SCF process are small vessel dysfunction [4], dif-
fuse atherosclerosis [5], inflammation [6], and in-
creased platelet aggregability [7]. It is also hypothe-
sized that SCF may be a form of atherosclerosis
involving small vessels because of its close relation-
ship with cardiovascular risk factors and its patho-
genesis overlapping with that of atherosclerosis [8].
Moreover, previous studies have shown that, simi-
lar to coronary artery disease, SCF is associated
with increased cardivascular mortality as well [9].
The more the number of affected vessels rises
in coronary artery disease, the lower the survival
rate [10], however, there is no study on this sub-
ject in SCF patients. Elevated thrombogenicity,
another factor believed to involve in the SCF patho-
genesis, is known to have a relationship with in-
creased hemoglobin (Hb) and mean platelet volume
(MPV) [11, 12]. Platelet volume is a marker of plate-
let activation and it is measured by using MPV [13].
Previous studies have shown that high MPV levels
are associated with cardiovascular risk factors [14]
and were increased in acute myocardial infarction,
coronary ectasia, and SCF [15–17] with a poor prog-
nosis [18].
While there are various studies about the re-
lationship among presence of SCF, hematologic in-
dices and cardiovascular risk factors [8, 17], there
is no study focusing on their relationship with the
extent of SCF. In our study, for the first time in the
literature, we aimed to investigate the relationship
between the extent of SCF, and hematologic indi-
ces and cardiovascular risk factors.
Methods
Patient selection
In this study, 2467 patients who received cor-
onary angiography between April 2009 and Novem-
ber 2010 were retrospectively evaluated. All the
patients included in our study had received coro-
nary angiography because of chest pain or objective
signs of ischemia (treadmill exercise or myocardial
SPECT). One hundred and seven SCF patients
were found on coronary angiograms. Fifty patients
with SCF were excluded from the study for the fol-
lowing reason; history of coronary artery disease
or sign of coronary artery disease on coronary an-
giograms (n = 17), coronary ectasia on coronary
angiograms (n = 11) moderate to severe valvular
heart disease and heart failure (n = 3), left ventri-
cular (LV) hypertrophy (n = 2), anemia (n = 8), end-
stage renal disease (ESRD) (n = 2), inflammatory
diseases (n = 2), malignancy (n = 1), peripheral or
cerebral artery disease (n = 2), thrombocytopenia
(n=1), and thyroid gland dysfunction (n = 1). Fi-
nally, 57 patients with SCF (experimental group)
were included in the study. Control group consist-
ed of 90 patients with age- and gender-matched
subjects who were selected in a consecutive man-
ner from the catheterized patients during the same
study period and who proved to have normal coro-
nary angiograms. Control subjects selected from
patients without exclusion criteria. Routinely mea-
sured laboratory and clinical parameters (e.g. dia-
betes mellitus [DM], hypertension [HTN], hyper-
cholesterolemia, smoking, family history of cardio-
vascular disease, height and weight) of the patients
were obtained from the medical records. In cases
having dubious or inconsistent records, patients
were contacted directly via phone.
Transthoracic echocardiography was carried
out before discharge by a system V (Vingmed, GE)
device using 2.5 MHz phased-array transducer.
Recordings were performed while the patients were
in the left lateral decubitus position. The LV ejec-
tion fraction was measured using modified Simp-
son’s rule according to the most recent guidelines
[19]. Our study was approved by the local ethics
committee.
Coronary angiography
In our clinic, coronary angiography is routine-
ly performed by Judkins method using iohexol (Om-
nipaque, Nycomed Ireland ltd., Cork, Ireland). Dur-
ing each injection, 6–10 mL contrast agent is man-
ually delivered and nitroglycerin is not routinely
applied. The coronary flow rates of all patients were
measured by the Thrombolysis In Myocardial In-
farction (TIMI) frame count (TFC) method with
cineangiography at 25 frames per second. Since the
left anterior descending (LAD) artery is usually
longer than other coronary arteries, the corrected-
TFC of the LAD artery was calculated by dividing
TFC by 1.7. The TFC of the LAD was assessed ei-
ther in right anterior oblique projection with cau-
dal angulation or left anterior oblique projection
with cranial angulation, while the assessments of
the left circumferential (LCx) artery and right co-
ronary artery (RCA) were usually performed in
straight left anterior oblique projection. TFC for
each coronary artery was determined from a distal
marking point specific for the coronary artery of
interest [20]. Coronary angiograms were assessed
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independently by two invasive cardiologists who
were blinded to the clinical findings.
Laboratory measurements
In our hospital the blood samples are collected
from the antecubital vein by an atraumatic puncture
prior to the coronary angiography and are sent to
the laboratory for analysis within 1 hour after col-
lection. Routinely venous blood is collected in a tube
containing K3 EDTA for measurement of hemato-
logic indices in all patients undergoing the coronary
angiography. Hematologic indices are evaluated
from complete blood count (CBC) analysis per-
formed by a Coulter LH 780 Hematology Analyzer
(Beckman Coulter Ireland Inc. Mervue, Galway,
Ireland).
Definitions
Stable angina was defined as discomfort in the
chest, jaw, shoulder, back, or arms, typically elicit-
ed by exertion or emotional stress, and relieved by
rest or nitroglycerin. HTN was defined as systolic
blood pressure > 140 mm Hg and/or a diastolic
blood pressure > 90 mm Hg, or use of antihyper-
tensive medications. The diagnosis of DM was
based on previous history of diabetes treated with
or without medical therapy. Hypercholesterolemia
was described as total cholesterol ≥ 200 mg/dL.
Body mass index (BMI) was calculated by dividing
the weight (kg) of an individual by the square of his/
/her height (m). A BMI value ≥ 30 kg/m2 was de-
fined as obese. Current smokers were defined as
having a history of smoking for a certain period
within the past year. Anemia on admission was de-
fined in accordance with the World Health Organi-
zation criteria, as having a baseline hemoglobin con-
centration value less than 13 mg/dL in men and less
than 12 mg/dL in women. The glomerular filtration
rate (GFR) was estimated by the simplified Modifi-
cation of Diet in Renal Disease Equation [21]. Re-
nal insufficiency was described as a GFR value
< 60 mL/min/1.732 m2. Patients were considered
as having ESRD if they were dependent on chronic
dialysis.
SCF was defined as a corrected TFC greater
than two standart deviations from the normal range
(40.8 frames for LAD, 29.8 frames for LCx, and
27.3 frames for RCA), while normal coronary flow was
described as a corrected TFC within two standart
deviations of normal range reported for the related
vessel [20]. Patients with SFC were categorized
as non-extensive (1 vessel, Group 1) and extensive
(> 1 vessels, Group 2) SCF cases relative to the
number of vessels affected by the slow flow. Mean
TFC for each subject was calculated by dividing the
total of corrected LAD, LCx and RCA values by
three.
Statistical analysis
Continuous variables are expressed as mean ±
± SD. Categorical variables are expressed as per-
centages. To compare parametric continuous vari-
ables, Student’s t test were used; to compare non-
parametric continuous variables, Mann-Whitney U
were used. Chi-square test was used to compare the
categorical variables. Multivariate logistic regres-
sion analysis was used to identify the independent
predictors of presence and extent of coronary slow
flow. All variables showing significance values < 0.1
in univariate analysis (DM, hypercholesterolemia,
current smoker, family history of cardiovascular
disease, obesity, Hb, MPV, and medications) were
included in the model. Association between varia-
bles was tested using Spearman’s or Pearson’s
correlation coefficient, when appropriate. Two-
-tailed p values < 0.05 were considered as statisti-
cally significance. All statistical studies were car-
ried out with the SPSS program (version 15.0,
SPSS, Chicago, Illinois, USA).
Results
Among the 147 patients (mean age 52.7 ± 10.0,
53.7% male), MPV ranged from 6.5 fL to 11.7 fL
(median 7.9 fL, mean 8.1 ± 0.8 fL). The baseline
characteristics of angiographic normal vessels or
those with angiographic SCF, are summarized in
Table 1. In patients with SCF, DM, hypercholes-
terolemia, and smoking were more common, and
they also exhibited significantly higher Hb (Fig. 1A)
and MPV (Fig. 1B) values. When SCF patients and
controls were compared with regard to TFC (re-
garding both mean and individual values), SCF pa-
tients demonstrated significantly higher TFC find-
ings compared with the control group (p < 0.001).
Moreover, SCF was determined to affect RCA
the most (64.9%), followed by LAD (57.9%) and LCx
(38.6%). SCF was observed to have a tendency to
affect a single vessel (49.1%) or two vessels
(40.4%); whereas three-vessel involvement was
less common (10.5%).
Statistically significant variables of univariate
analysis were included in the multivariate logistic
regression analysis. DM (OR = 3.64, 95% CI 1.15–
–10.43, p = 0.03), hypercholesterolemia (OR = 4.94,
95% CI 1.99–12.21, p = 0.001), smoking (OR = 3.54,
95% CI 1.43–8.72, p = 0.002), Hb (OR = 1.69, 95%
CI 1.22–2.36, p = 0.002), and MPV (OR = 2.52, 95%
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CI 1.43–4.44, p = 0.001) were the independent cor-
relates of SCF presence (Table 2). The extensive
and non-extensive SCF cases (Group 1 and 2) are
compared in Table 3. Group 2 had higher rates for
DM and family history of cardiovascular disease, as
well as significantly increased MPV (Fig. 1C). In the
multiple logistic regression analysis, only MPV
(OR = 2.13, 95% CI 1.05–4.33, p = 0.03) was found
to be the independent correlate of extent of SCF.
Moreover, MPV was found to show a moderate cor-
Table 1. Baseline characteristics of angiographic normaly and slow coronary flow patients.
Variables Slow flow (n = 57) Normal flow  (n = 90) P
Age [years] 53.7 ± 10.7 51.9 ± 9.5 0.18
Male sex 32 (56.1%) 47 (52.2%) 0.64
Diabetes mellitus 17 (29.8) 8 (8.9%) 0.001
Hypertension 23 (40.4%) 30 (33.3%) 0.38
Hypercholesterolemia 28 (49.1%) 17 (18.9%) < 0.001
Current smokers 25 (43.9%) 22 (24.4%) 0.01
Family history 11 (19.3%) 25 (27.8%) 0.24
BMI ≥ 30 kg/m2 13 (22.8%) 11 (12.2%) 0.09
GFR< 60 mL/mn/1.73 m2 3 (5.3%) 7 (7.8%) 0.55
Aspirin use 13 (22.8%) 28 (31.1%) 0.27
Beta-blocker use 8 (14%) 13 (14.4%) 0.94
ACE inhibitor use 12 (21.1%) 21 (23.3%) 0.74
Statin use 9 (15.8%) 12 (13.3%) 0.67
Diuretic use 10 (17.5%) 10 (11.1%) 0.26
Nitrates 6 (10.5%) 12 (13.3%) 0.61
Calcium canal blokers 9 (15.8%) 12 (13.5%) 0.69
LVEF [%] 61.4 ± 5.7 60.2 ± 8.7 0.42
Hemoglobine [g/dL] 15.0 ± 1.3 14.2 ± 1.2 0.001
MCV [fL] 88.2 ± 4.9 87.9 ± 3.4 0.70
WBC [103/µL] 7.5 ± 2.4 7.7 ± 1.7 0.17
Platelet [mm3] 245.7 ± 58.1 232.9 ± 36.3 0.20
MPV [fL] 8.4 ± 1.0 7.9 ± 0.6 0.002
RDW [%] 13.9 ± 1.5 13.7 ± 0.6 0.80
Hemodynamic data on coronary angiography:
SBP [mm Hg] 126.1 ± 12.8 129.9 ± 14.7 0.21
DBP [mm Hg] 76.5 ± 8.9 79.2 ± 10.7 0.15
Heart rate [bpm] 77.9 ± 14.2 79.1 ± 11.9 0.51
TIMI frame count:
LAD (corrected) 37.8 ± 12.1 27.2 ± 4.3 < 0.001
LCx 28.7 ± 9.0 21.0 ± 3.9 < 0.001
RCA 32.7 ± 9.8 21.1 ± 3.8 < 0.001
Mean 33.1 ± 6.3 23.1 ± 2.7 < 0.001
Distribution of slow flow:
LAD 33 (57.9%)
LCx 22 (38.6%)
RCA 37 (64.9%)
Number of slow flow vessels:
One vessel 28 (49.1%)
Two vessels 23 (40.4%)
Three vessels 6 (10.5%)
Results are expressed as mean ± SD and percentage; ACE — angiotensin converting enzyme; BMI — body mass index; DBP — diastolic blood pressure;
GFR — glomerular filtration rate, LAD — left anterior descending artery; LCx — left circumflex artery; LVEF — left ventricular ejection fraction;
MCV — mean corpuscular volume; MPV — mean platelet volume; RCA — right coronary artery; RDW — red cell distribution width; SBP — systolic
blood pressure; TIMI — Thrombolysis In Myocardial Infarction; WBC — white blood cell
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relation with the number of vessels affected by SCF
(r = 0.33, p = 0.01, Fig. 1D) and TFC values (mean
TFC: r = 0.43, p< 0.001; LAD TFC: r = 0.27,
p = 0.001; LCx TFC: r = 0.33, p < 0.001; RCA TFC:
r = 0.31, p < 0.001, Figs. 2A–D).
Discussion
This is the first study to evaluate the relation-
ship between the extent of SCF, and cardiovascu-
lar risk factors and hematologic indices. We found
Figure 1. A, B. Hemoglobin and mean platelet volume (MPV) values of patients with and without slow coronary flow
(SCF); C. The relationship of MPV with extensive and non-extensive SCF; D. The relationship between MPV and the
number of vessels with SCF.
A B
Table 2. Independant predictors of slow coronary flow in multivariate logistic regression analysis.
Variables Univariate OR (95% CI) P Mulivariate OR (95% CI) P
Diabetes mellitus 4.35 (1.73–10.94) 0.001 3.64 (1.15–10.43) 0.03
Hypercholesterolemia 4.14 (1.97–8.69) < 0.001 4.94 (1.99–12.21) 0.001
Current smoker 2.41 (1.18–4.91) 0.01 3.54 (1.43–8.72) 0.006
BMI ≥ 30 kg/m2 2.12 (0.87–5.13) 0.09 1.69 (1.22–2.36) 0.18
Hemoglobine [g/dL] 1.57 (1.19–2.07) 0.001 1.69 (1.22–2.36) 0.002
MPV [fL] 2.32 (1.44–3.72) < 0.001 2.52 (1.43–4.44) 0.001
BMI — body mass index; MPV — mean platelet volume; OR — odds ratio; CI — confidence interval
C D
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that increased baseline MPV values were indepen-
dently associated with the presence and extent of
SCF. Moreover, in our study, we observed that in-
creased Hb was independently associated with the
presence of SCF.
Although the pathophysiology of SCF is not
completely clear, based on its histopathologic chara-
cteristics (e.g. degeneration of the endothelial cells
with narrowing of the vascular lumina) [22], accom-
panying atherosclerosis [5], close relationship with
inflammatory parameters (e.g. CRP) [6], and in-
creased platelet aggregability [7], it is hypothesized
that SCF may be a form of atherosclerosis involving
small vessels. Similarly, recent IVUS (Intravascular
ultrasound) and fractional flow reserve studies have
shown early diffuse atherosclerosis and increased
epicardial resistance in vessels with SCF [5].
Endothelial dysfunction is the most plausible
mechanism in terms of SCF pathogenesis [22].
There is a close relationship between the endothe-
lial dysfunction, and inflammatory parameters and
cardiovascular risk factors (e.g. smoking, hyper-
cholesterolemia) [23]. In this study, we did not eva-
luate the inflammatory parameters, however, pre-
vious studies have already shown that inflammato-
ry parameters exhibit an increase in patients with
SCF [6]. Therefore, our findings were in agreement
with the previous studies in terms of showing an
independent relationship between the presence of
SCF and cardiovascular risk factors (e.g. DM, hy-
percholesterolemia and smoking) which are known
to be closely associated with inflammation and en-
dothelial dysfunction [2, 8]. It is known that raised
inflammatory parameters damage endothelial gly-
cocalyx, the luminal surface protecting endothe-
lium, and lead to endothelial dysfunction [24].
Platelets assume a critical role in the regula-
tion of blood flow and thrombogenic events [25].
Table 3. Baseline characteristics with and without extent of slow coronary flow.
Variables Group 1 (n = 28 ) Group 2 (n = 29) P
Age [years] 52.4 ± 9.4 55.1 ± 11.9 0.27
Male sex 14 (50%) 18 (62.1%) 0.35
Diabetes mellitus 4 (14.3%) 13 (44.8%) 0.01
Hypertension 12 (42.9%) 11 (37.9%) 0.70
Hypercholesterolemia 16 (57.1%) 12 (41.4%) 0.23
Current smoker 13 (46.4%) 12 (41.4%) 0.70
Family history 2 (7.1%) 9 (31%) 0.02
BMI ≥ 30 kg/m2 5 (17.9%) 8 (27.6%) 0.38
GFR < 60 mL/mn/1.73 m2 1 (3.6%) 2 (6.9%) 0.57
Aspirin use 5 (17.9%) 8 (27.6%) 0.38
Beta-blocker use 2 (7.1%) 6 (20.7%) 0.14
ACE inhibitor use 8 (28.6%) 4 (13.8%) 0.17
Statin use 6 (21.4%) 3 (10.3%) 0.25
Diuretic use 5 (17.9%) 5 (17.2%) 0.95
Nitrates 4 (14.3%) 2 (6.9%) 0.36
Calsium canal blokers 7 (25%) 2 (6.9%) 0.06
LVEF [%] 61.4 ± 6.1 61.3 ± 5.3 0.71
Hemoglobine [g/dL] 15.2 ± 1.1 14.7 ± 1.4 0.22
MCV [fL] 88.4 ± 5.1 88.0 ± 4.7 0.86
WBC [103/µL] 7.5 ± 2.9 7.5 ± 1.9 0.50
Platelet [mm3] 258.7 ± 59.2 233.2 ± 55.2 0.19
MPV [fL] 8.1 ± 0.8 8.7 ± 1.1 0.04
RDW [%] 13.7 ± 1.4 14.2 ± 1.7 0.23
Hemodynamic data on coronary angiography:
SBP [mm Hg] 124.1 ± 13.3 128.0 ± 12.4 0.29
DBP [mm Hg] 76.1 ± 8.9 76.9 ± 9.2 0.71
Heart rate [bpm] 77.1 ± 15.1 78.7 ± 13.5 0.59
Mean TIMI frame count 28.3 ± 2.7 37.7 ± 5.2 < 0.001
Results are expressed as mean ± SD and percentage; Group 1 — non-extensive SCF; Group 2 — extensive SCF; rest abbreviations as in Table 3
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Elevated thrombogenic tendency is one of the oth-
er subjects studied with regard to SCF pathogene-
sis [17]. Gokce et al. [7] showed that patients with
SCF had increased platelet aggregability in the ris-
tocetin, collagen and adenosine diphosphate groups
than in the control group. Platelet volume is a in-
dex of platelet activation and it is measured by us-
ing MPV [13]. Increased MPV values suggest large
platelets with more dense granules. Large platelets
secrete high amounts of prothrombogenic throm-
boxane A2, serotonin and procoagulant membrane
proteins like sP-selectin [15, 17, 25]. Moreover,
large platelets are less sensitive to the antiaggre-
gation and antisecretion properties of prostacyclin
[16]. However, previous studies have reported that
high MPV levels are related with cardiovascular
risk factors [14] and were increased in cardiac con-
ditions [15–17] with a poor prognosis [18]. In our
Figure 2. The relationship between mean platelet volume (MPV) and Thrombolysis In Myocardial Infarction (TIMI)
frame count (TFC) values (mean and individual values for each artery); rest abbreviations as in Table 1.
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study, we determined that MPV levels were not
only associated with the presence of SCF, but also
associated with the extent of SCF. These results
show an association with a increase in MPV in pa-
tients with SCF.
The viscosity of blood is the resistance of blood
against the flow and it is observed to increase in
coronary artery disease patients [26]. Blood viscosi-
ty is a risk factor in cardiovascular events [27] and
it is influenced by the same parameters, one of
which is hematocrit [28]. In this study, we did not
measure viscosity in SCF patients, however, pre-
vious studies have shown that SCF patients present
with raised blood viscosity [29]. Our study shows
for the first time that increased Hb values an asso-
ciated with presence of SCF. As in atherosclerosis
cases, blood viscosity is raised in SCF patients be-
cause of increased platelet adhesion to subendo-
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thelium, elevated protein infiltration into the arte-
rial wall, and altering local shear forces [30].
There is no consensus on the treatment pro-
tocols for SCF patients. Generally, as in coronary
artery disease patients, those cases are treated by
agents against angina attacks such as organic ni-
trates, beta–blockers and calcium channel blockers
along with acetylsalicylic acid and statin therapy
against a possible atherosclerotic pathogenesis.
However, these therapies oftenly fail to control the
angina attacks. In our study, we did not focus on the
efficacy of a certain agent, however, because of pa-
tients with SCF have atherosclerosis, inflammation,
endothelial dysfunction, and elevated thromboge-
nicity, they may need an aggressive antiplatelet
therapy with modification of risk factors and reduces
MPV values, particularly in patients with extensive
SCF. However, further multicenter randomized
prospective studies are required for verification.
Limitations of the study
First, this was a cross-sectional study, there-
fore, we did not perform long-term analyses. Se-
cond, since normal coronary artery was defined
based on the angiographic appearance, all the athe-
rosclerotic plaques could not be excluded.
Conclusions
An increased baseline MPV value was found to
be an associated with presence and extent of SCF.
Our study may assist in better understanding the
SCF pathogenesis.
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